Nektar Therapeutics (NKTR) Equity Income (2025 - 2026)
Nektar Therapeutics (NKTR) recorded quarterly Equity Income of -$1.8 million in Q1 2026, down 30.01% quarter-over-quarter from -$1.3 million in Q4 2025, and up 60.77% on a YoY basis from -$1.1 million in Q1 2025.
Nektar Therapeutics (NKTR) Equity Income (2025 - 2026) Analysis & Trends
Nektar Therapeutics' Equity Income history runs 2 years deep, the most recent figure standing at -$1.8 million for Q1 2026.
- In Q1 2026, Equity Income rose 60.77% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at -$6.0 million (down 34.86% YoY), while the FY2025 annual figure was -$8.7 million, changed N/A from the prior year.
- Equity Income was -$1.8 million for Q1 2026 at Nektar Therapeutics, down from -$1.3 million in the prior quarter.
- In the past five years, Equity Income ranged from a high of -$534000.0 in Q3 2025 to a low of -$4.5 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Nektar Therapeutics | 1.51 Bn | 939.55 Mn | 3.16 Mn | -1.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.75 Mn |
| Dec 31, 2025 | -1.35 Mn |
| Sep 30, 2025 | -534,000.00 |
| Jun 30, 2025 | -2.39 Mn |
| Mar 31, 2025 | -4.46 Mn |